Safety and Efficacy of Tofacitinib for Chronic Granulomatous Disease With Inflammatory Complications
NCT ID: NCT05104723
Last Updated: 2025-12-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ENROLLING_BY_INVITATION
PHASE1/PHASE2
20 participants
INTERVENTIONAL
2022-08-12
2027-01-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Chronic granulomatous disease (CGD) is a disease of the immune system, which is how the body fights germs. People with CGD get infections easily and have other health problems. Some medicines to treat CGD have a lot of side effects and do not always work. Researchers want to see if a new drug can help.
Objective:
To see if tofacitinib is safe to use for treating chronic CGD.
Eligibility:
Adults aged 18 and older with CGD who have not had success with other treatments and who are enrolled on NIH study # 93-I-0119.
Design:
Participants will be screened with the following:
Physical exam
Medical history
Blood, urine, and stool tests
Pregnancy test, if needed
An upper gastrointestinal endoscopy and/or colonoscopy, if needed for their symptoms. Tissue samples will be collected.
Skin assessment, if needed
Participants will repeat some screening tests at visits.
Participants will complete questionnaires about their general health and how CGD affects their daily life. Photographs will be taken of their skin, if needed. They will have lung function tests, if needed. They will have a computed tomography (CT) scan of the chest, abdomen, and pelvis, if needed. A CT scan uses X-rays to create pictures of the inside of the body.
Participants will gradually reduce the amount of some CGD medicines they take. Then they will take tofacitinib as a pill twice a day or once a day for 3 months. They will keep a drug diary. They will have monthly study visits. They will have a follow-up visit about 1 month after their last study drug visit.
Participation will last for about 6 months.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This is a phase 1/2 open-label trial to study the safety and to explore the biological efficacy of tofacitinib in patients with confirmed and symptomatic inflammatory complications (gastrointestinal \[GI\], skin, lung) related to chronic granulomatous disease (CGD). After a 3-month regimen, participants inflammatory complications will be objectively assessed.
Primary Objective:
To assess the safety of tofacitinib during the study period in patients with CGD.
Secondary Objectives:
1. To assess the overall clinical response for the specific inflammatory manifestations.
2. To assess the biological effect of tofacitinib on interferon (IFN)-induced gene expression in CGD.
Primary Endpoints:
1. Rate of infection.
2. Rate of treatment-related toxicities.
3. Rate of adverse events (AEs).
4. Incidence of serious bacterial, mycobacterial, fungal, or viral infections defined as infections that require medical assessment or hospitalization.
Secondary Endpoints:
CGD-related inflammatory bowel disease (IBD):
1. Change in modified Harvey-Bradshaw Index (HBI).
2. Change in histopathological endoscopy.
Inflammatory lung disease:
1. Change in forced expiratory volume (FEV1).
2. Change in diffusing capacity for carbon monoxide (DLCO).
3. Change in computed tomography (CT) radiography.
4. Change in 6-minute walk.
Skin disease:
1\. Change in presence of skin flares or ulcerations by objective photography evaluation.
Gene expression:
1.Change in IFN gene module enrichment score derived from whole blood RNA expression data.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
XELJANZ (tofacitinib)
Tofacitinib is self-administered orally at 5 mg twice per day or 11 mg once per day for 3 months.
XELJANZ (tofacitinib)
The XELJANZ 5-mg tablets or 11-mg XR tablets will taken orally twice daily or once daily, respectively, in this study.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
XELJANZ (tofacitinib)
The XELJANZ 5-mg tablets or 11-mg XR tablets will taken orally twice daily or once daily, respectively, in this study.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Aged \>=18 years.
2. Enrolled on NIH study 93-I-0119.
3. Has a documented diagnosis of one or more of the following and is not controlled under current therapy (per investigator assessment):
1. Endoscopically diagnosed mild-to-severe CGD-related IBD.
2. Radiographic or PFT changes (DLCO\<60%, FEV1\<70%) consistent with CGD-related inflammatory lung disease.
3. Any inflammatory skin disease related to CGD (eg, hidradenitis suppurativa or granulomatous skin disease).
4. Able to provide informed consent.
5. Participants who can become pregnant or who can impregnate their partner must agree to use at least one highly effective method of contraception when engaging in sexual activities that can result in pregnancy, starting at the first dose of tofacitinib until 2 days after the last dose. Highly effective methods include a barrier (eg, condom, diaphragm, cervical cap), intrauterine device, or hormonal contraception.
Exclusion Criteria
1. Known allergy or hypersensitivity to any component of the tofacitinib formulation.
2. Known allergy or hypersensitivity to any component of the acyclovir or valacyclovir formulation.
3. Active or latent tuberculosis.
4. Infection with hepatitis B or C, or HIV.
5. Active EBV infection.
6. History of GI perforation.
7. History of malignancy (except for nonmelanoma skin cancer).
8. Concomitant use of acetylsalicylic acid and/or NSAIDs that cannot be safely discontinued.
9. History of connective tissue disease.
10. End-stage renal disease or chronic kidney disease, defined as estimated glomerular filtration rate (eGFR) \<15 mL/min/1.73 m\^2.
11. Evidence of other invasive or systemic fungal, bacterial, or viral infections requiring therapy.
12. Pregnant.
13. Breastfeeding.
14. Current use of inhaled tobacco products, vaping product, inhaled cannabis, or other illicit inhaled drugs.
15. Current use of strong CYP3A4 inducer and unable to discontinue at least 14 days before beginning of tofacitinib regimen.
16. Concomitant medical condition that could interfere with study drug evaluation or that is a contraindication to the proposed investigational treatment based upon known agent safety profile or toxicities.
17. Any of the following laboratory abnormalities:
1. Alkaline phosphatase and either ALT or AST \>2.5 times the upper limit of normal (ULN).
2. Serum creatinine level \>5 mg/dL.
3. Absolute neutrophil count (ANC) \<1000 cells/microL.
4. Lymphocyte count \<500 cells/microL.
18. History of unprovoked deep vein thrombosis, pulmonary embolism, or other thrombotic events.
19. History of heart failure.
20. Current immobilization, ie, bed-bound and unable to ambulate.
21. Exposure to any investigational agent within the last 4 weeks.
22. Any other finding that, in the judgment of the investigator, would interfere with, or serve as a contraindication to, protocol adherence, assessment of safety or reactogenicity, or a participant s ability to give informed consent, or increase the risk of having an adverse outcome from participating in the study.
18 Years
99 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Christa S Zerbe, M.D.
Role: PRINCIPAL_INVESTIGATOR
National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Institutes of Health Clinical Center
Bethesda, Maryland, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Panes J, Sandborn WJ, Schreiber S, Sands BE, Vermeire S, D'Haens G, Panaccione R, Higgins PDR, Colombel JF, Feagan BG, Chan G, Moscariello M, Wang W, Niezychowski W, Marren A, Healey P, Maller E. Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials. Gut. 2017 Jun;66(6):1049-1059. doi: 10.1136/gutjnl-2016-312735. Epub 2017 Feb 16.
Henrickson SE, Jongco AM, Thomsen KF, Garabedian EK, Thomsen IP. Noninfectious Manifestations and Complications of Chronic Granulomatous Disease. J Pediatric Infect Dis Soc. 2018 May 9;7(suppl_1):S18-S24. doi: 10.1093/jpids/piy014.
Related Links
Access external resources that provide additional context or updates about the study.
NIH Clinical Center Detailed Web Page
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
000064-I
Identifier Type: -
Identifier Source: secondary_id
10000064
Identifier Type: -
Identifier Source: org_study_id